Assessment of OMT-28, a synthetic analog of omega-3 epoxyeicosanoids, in patients with persistent atrial fibrillation: Rationale and design of the PROMISE-AF phase II study

We designed a placebo controlled, double-blind, randomized, dose-finding phase II study on OMT-28 in the maintenance of sinus rhythm after electrical cardioversion (DCC) in patients with persistent atrial fibrillation (PROMISE-AF). OMT-28 is a first-in-class, synthetic analog of 17,18-epoxyeicosatet...

Descripción completa

Detalles Bibliográficos
Autores principales: Berlin, Sarah, Goette, Andreas, Summo, Luciana, Lossie, Janine, Gebauer, Alexander, Al-Saady, Naab, Calo, Leonardo, Naccarelli, Gerald, Schunck, Wolf-Hagen, Fischer, Robert, Camm, A.John, Dobrev, Dobromir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356118/
https://www.ncbi.nlm.nih.gov/pubmed/32685659
http://dx.doi.org/10.1016/j.ijcha.2020.100573

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356118/
https://www.ncbi.nlm.nih.gov/pubmed/32685659
http://dx.doi.org/10.1016/j.ijcha.2020.100573

Ejemplares similares